Niedrobnokomórkowy rak płuca: badanie fazy II/III leku adagrasib i pembrolizumab
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7